GREY:IMVIQ - Post by User
Comment by
Breakthorough1on Jul 01, 2023 6:58am
193 Views
Post# 35523439
RE:2nd dead line
RE:2nd dead lineCheck a case like that of Vascular Biogenics (VBL).
The 21 of July 2022 they announce a failure on their trial of VB-111 in platinum-resistant ovarian cancer. The program was stoppped and the stock fell 90% on a day.
The 15 of august 2022 VBL announced the exploratiok of "strategic options", in similar terms that IMV did the 16th of march (though DPX has not failed in any trial).
The 23 of february 2023 (six months later), VBL announced a merger with Notable Labs. The stock has been recovering since that date.
Hope the radical decission of IMV has been related to the timing of a transaction of this kind. The clinical data are much much better than those of VB-111. In any case, we willl knoe soon.